Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma

NCT05506410 is registered in ClinicalTrials.gov with Zhengzhou University as lead sponsor.

NCT NCT05506410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05506410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
Lead sponsor
Zhengzhou University
Phase
Observational
Overall status
Recruiting
Start date
August 12, 2022
Completion date
December 30, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed mantle cell lymphoma